+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer

Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer

Anticancer Research 32(11): 5087-5091

This study aimed to determine the relationship between the pre-operative metabolic tumor volume (MTV) and the disease-free survival (DFS) of patients with stage I non-small cell lung cancer (NSCLC) using F-18 2-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography-computed tomography (PET-CT) scanning. Data from sixty patients with stage I NSCLC who had undergone preoperative F-18 FDG PET-CT scanning were retrospectively analyzed. The early and late maximum standardized uptake values (eSUVm and lSUVm, respectively) were measured from attenuation-corrected F-18 FDG PET-CT images. Three MTV segmentation methods were applied as an isocontour at an early SUV of 2.5 (MTV2.5) or using fixed thresholds of either 40% (MTV40%) or 50% (MTV50%) of the maximum intratumoral F-18 FDG activity. DFS was compared by employing the Kaplan-Meier method, using the median values as cutoffs for each parameter. The log-rank test and Cox regression were performed to explore the effect of the different MTV variables on DFS. Time-dependent receiver operating characteristic (ROC) curves were created to evaluate the predictive performance. During a median follow-up duration of 24 months, two patients died of disease progression, and 11 experienced recurrent tumors (eight intrathoracic tumors, two distant metastasis, and one both types of recurrences). The univariate analyses showed that pathological stage 1B, histological type of squamous cell carcinoma, male sex, maximum tumor size over 2 cm, eSUVm, lSUVm, and MTV2.5 were associated with reduced DFS. Patients who had tumors with large eSUVm or large lSUVm had a significantly lower 2-year DFS, compared with patients who had smaller tumors (65% vs. 96%, p=0.002; 63% vs. 96%, p=0.000). Patients with an MTV2.5 greater than 9.8 ml had a lower 2-year DFS than those with an MTV of 9.8 ml or greater (59 vs. 85%, p=0.02). However, multivariate analysis showed that lSUVm over 3.4 was the only parameter that exhibited an impact on DFS (p=0.05, hazard ratio=10.7), and the observed influence was marginal. For patients with stage I NSCLC treated with surgery, preoperative MTV parameters have a limited prognostic value for predicting DFS.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 055214609

Download citation: RISBibTeXText

PMID: 23155285

Related references

Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer. Medical Oncology 30(1): 352, 2013

Survival Prognostic Value of Morphological and Metabolic variables in Patients with Stage I and II Non-Small Cell Lung Cancer. European Radiology 25(11): 3361-3367, 2015

Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis. Bio-Medical Materials and Engineering 24(6): 3091-3103, 2014

Value of preoperative inflammation-based prognostic scores in predicting overall survival and disease-free survival in patients with gastric cancer. Annals of Surgical Oncology 21(6): 1998-2004, 2014

Prognostic factors in resected stage I non-small cell lung cancer with a diameter of 3 cm or less: visceral pleural invasion did not influence overall and disease-free survival. Journal of Thoracic and Cardiovascular Surgery 134(3): 638-643, 2007

The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib. Tuberculosis and Respiratory Diseases 78(4): 315-320, 2015

RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. Journal of Clinical Oncology 22(10): 1878-1885, 2004

CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification. Journal of Thoracic Oncology 5(5): 649-657, 2010

Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score. Tumour Biology 29(4): 272-277, 2008

Whole body metabolic tumor volume is a prognostic marker in patients with newly diagnosed stage 3B non-small cell lung cancer, confirmed with external validation. European Journal of Hybrid Imaging 1(1): 8, 2017

Metabolic Tumor Volume Predicts Overall Survival in Patients With Stage III Non-Small Cell Lung Cancer Treated on ACRIN 6668/RTOG 0235. International Journal of Radiation Oncology*biology*physics 90(5): S3-S4, 2014

Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer. Nuclear Medicine Communications 34(10): 959-963, 2013

Exploring Stage I non-small-cell lung cancer: development of a prognostic model predicting 5-year survival after surgical resection†. European Journal of Cardio-Thoracic Surgery 47(6): 1037-1043, 2015

Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Lung Cancer 74(1): 112-117, 2011

Development and validation of two prognostic nomograms for predicting survival in patients with non-small cell and small cell lung cancer. Oncotarget 8(38): 64303-64316, 2017